Establishment of the Black-Tailed Prairie Dog (Cynomys ludovicianus) as a Novel Animal Model for Comparing Smallpox Vaccines Administered Preexposure in both High- and Low-Dose Monkeypox Virus Challenges
Open Access
- 1 August 2011
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 85 (15), 7683-7698
- https://doi.org/10.1128/jvi.02174-10
Abstract
The 2003 monkeypox virus (MPXV) outbreak and subsequent laboratory studies demonstrated that the black-tailed prairie dog is susceptible to MPXV infection and that the ensuing rash illness is similar to human systemic orthopoxvirus (OPXV) infection, including a 7- to 9-day incubation period and, likely, in some cases a respiratory route of infection; these features distinguish this model from others. The need for safe and efficacious vaccines for OPVX in areas where it is endemic or epidemic is important to protect an increasingly OPXV-naïve population. In this study, we tested current and investigational smallpox vaccines for safety, induction of anti-OPXV antibodies, and protection against mortality and morbidity in two MPXV challenges. None of the smallpox vaccines caused illness in this model, and all vaccinated animals showed anti-OPXV antibody responses and neutralizing antibody. We tested vaccine efficacy by challenging the animals with 10 5 or 10 6 PFU Congo Basin MPXV 30 days postvaccination and evaluating morbidity and mortality. Our results demonstrated that vaccination with either Dryvax or Acambis2000 protected the animals from death with no rash illness. Vaccination with IMVAMUNE also protected the animals from death, albeit with (modified) rash illness. Based on the results of this study, we believe prairie dogs offer a novel and potentially useful small animal model for the safety and efficacy testing of smallpox vaccines in pre- and postexposure vaccine testing, which is important for public health planning.Keywords
This publication has 81 references indexed in Scilit:
- Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of CongoProceedings of the National Academy of Sciences of the United States of America, 2010
- Vaccinia virus vaccines: Past, present and futureAntiviral Research, 2009
- Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE® against aerosolized rabbitpox virus in a rabbit modelVaccine, 2009
- Experimental infection of an African dormouse (Graphiurus kelleni) with monkeypox virusVirology, 2009
- Overexpression of IL-1α in Skin Differentially Modulates the Immune Response to Scarification with Vaccinia VirusJournal of Investigative Dermatology, 2009
- Vaccinia virus-specific CD8+ T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humansHuman Immunology, 2008
- Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virusProceedings of the National Academy of Sciences of the United States of America, 2008
- Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigensVirology, 2008
- Clinical and immunologic responses to multiple doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax® challengeVaccine, 2007
- DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challengeVirology, 2007